Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 13, 2017

View Archived Issues

Ionis Pharmaceuticals licenses drug to Dynacure

EMA's CHMP supports expanding Nplate indication

Preclinical evaluation of selective ATM kinase AZD-1390 inhibitor for treatment of glioblastoma

EMA committee recommends expanding approval of Orkambi

Discovery of novel ERK1/2 inhibitors with robust antitumor activity in vivo

CHMP issues positive opinion on Avastin biosimilar ABP-215

Neurimmune, Ono Pharmaceutical to collaborate on antibodies for neurodegenerative diseases

Devonian Health Group begins phase IIa study of Thykamine in atopic dermatitis

Benralizumab obtains positive opinion in E.U.

FDA accepts for review Sunovion's NDA for dasotraline

EMA committee confirms refusal of Fanaptum MAA

CFTR potentiator GLPG-2451 appears safe in first-in-human study

FDA expands approval of Bristol-Myers Squibb's Sprycel

Phase III results reported for ozanimod in relapsing MS

EMA grants PRIME designation to Mereo's BPS-804

Pfizer initiates phase I study of pegfilgrastim biosimilar PF-06881894

Wound healing improved with SNF-472 in hemodialysis patients with calciphylaxis

PharmaMar expects negative feedback for Aplidin MAA from EMA committee

University of Massachusetts divulges rAAV vectors encoding aspartoacylase

Novel Bcl-2-targeting drugs created at BioVentures

Dana-Farber Cancer Institute presents new anti-EGFR proteolysis-targeting chimera compounds

Baruch S. Blumberg Institute identifies novel glucosidase inhibitors

Five Prime, GlaxoSmithKline present novel neighbor of punc e11 polypeptides

Actelion studies ACT-709478 in patients with photosensitive epilepsy

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 19, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 19, 2025.
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.
ABS-1230 controls seizures in KCNT1-driven severe epilepsy
BioWorld Science
Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...